Skip to main content
Equibles
PRAX logo

PRAX · Praxis Precision Medicines, Inc.

Track PRAX — free

Use PRAX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRAX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$366.81 -1.65 (-0.45%) At close · Aug 14
Market Cap
$10.24B
Shares
27.92M

Praxis Precision Medicines, Inc. Earnings Call Transcripts

Every quarterly earnings call for Praxis Precision Medicines, Inc. (PRAX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$68.72M '22 Q1 22-05-09 ▼54.3% $357,000 −$32.68M '24 Q2 24-08-13 ▼35.5% $302,000 −$51.91M '24 Q3 24-11-06 ▼100% $ −$71.13M '25 Q2 25-08-04 ▼100% $ −$73.93M '25 Q3 25-11-05 LATEST ▼100% $ −$88.91M '25 Q4 26-02-19
Earnings call
FY26 · Q2
2026-08-06
Praxis Precision Medicines Second Quarter 2026 Financial Results Conference Call
Confident tone Commercial launch readiness Ulexacaltamide (Essential Tremor) NDA Relutrogene (SCN2A/8A) NDA and PDUFA
Diluted EPS
$-2.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE 2026
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Praxis Precision Medicines, Inc. Q1 FY2026 Earnings Call
Confident tone Vormatrigene (POWER 1/2/3) program Uliexacaltamide for Essential Tremor Emerald broad DE study enrollment
Diluted EPS
$-3.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Praxis Precision Medicines, Inc. Q4 FY2025 Earnings Call
Confident tone Relutrigine in DEEs Ulixacaltamide in essential tremor Regulatory and FDA interactions
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Praxis Precision Medicines, Inc. Q3 FY2025 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-3.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Praxis Precision Medicines, Inc. Q2 FY2025 Earnings Call
Confident tone RADIANT study efficacy results Pipeline and upcoming catalysts Safety and tolerability profile
Revenue
$
▼ 100% YoY
Diluted EPS
$-3.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-06
Praxis Precision Medicines, Inc. Q3 FY2024 Earnings Call
Confident tone Ulixacaltamide Phase 3 Essential Tremor Program Relutrigine in SCN2A and SCN8A DEEs Vormatrigine (PRAX-628) ENERGY Program in Epilepsy
Revenue
$302,000
▼ 35.5% YoY
Diluted EPS
$-2.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Praxis Precision Medicines, Inc. Q2 FY2024 Earnings Call
Revenue
$357,000
▼ 54.3% YoY
Diluted EPS
$-1.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Praxis Precision Medicines, Inc. Q1 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-22.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Praxis Precision Medicines, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Praxis Precision Medicines, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-15.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-17
Praxis Precision Medicines, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–12 of 12 earnings calls
Key facts CIK 1689548 CUSIP 74006W207 13F (30d) 306 filings 305 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)